{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:57:45Z","timestamp":1793696265212,"version":"4.5.1"},"reference-count":263,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41569-024-01037-7","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T09:02:35Z","timestamp":1715763755000},"page":"762-779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":172,"title":["Efferocytosis in atherosclerosis"],"prefix":"10.1038","volume":"21","author":[{"given":"Shaunak S.","family":"Adkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-2806","authenticated-orcid":false,"given":"Nicholas J.","family":"Leeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"1037_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0021-9150(96)06037-6","volume":"130","author":"M Crisby","year":"1997","unstructured":"Crisby, M. et al. Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis 130, 17\u201327 (1997).","journal-title":"Atherosclerosis"},{"key":"1037_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0021-9150(96)06018-2","volume":"129","author":"T Neunteufl","year":"1997","unstructured":"Neunteufl, T. et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 129, 111\u2013118 (1997).","journal-title":"Atherosclerosis"},{"key":"1037_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0008-6363(98)00212-0","volume":"41","author":"MR Bennett","year":"1999","unstructured":"Bennett, M. R. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc. Res. 41, 361\u2013368 (1999).","journal-title":"Cardiovasc. Res."},{"key":"1037_CR4","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0008-6363(99)00235-7","volume":"45","author":"MM Kockx","year":"2000","unstructured":"Kockx, M. M. & Herman, A. G. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res. 45, 736\u2013746 (2000).","journal-title":"Cardiovasc. Res."},{"key":"1037_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3349\/ymj.2000.41.6.740","volume":"41","author":"Y Wada","year":"2000","unstructured":"Wada, Y. et al. In vitro model of atherosclerosis using coculture of arterial wall cells and macrophage. Yonsei Med. J. 41, 740\u2013755 (2000).","journal-title":"Yonsei Med. J."},{"key":"1037_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/83301","volume":"7","author":"MA Lazar","year":"2001","unstructured":"Lazar, M. A. Progress in cardiovascular biology: PPAR for the course. Nat. Med. 7, 23\u201324 (2001).","journal-title":"Nat. Med."},{"key":"1037_CR7","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1172\/JCI117917","volume":"95","author":"MR Bennett","year":"1995","unstructured":"Bennett, M. R., Evan, G. I. & Schwartz, S. M. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J. Clin. Invest. 95, 2266\u20132274 (1995).","journal-title":"J. Clin. Invest."},{"key":"1037_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjcvp\/pvw037","volume":"3","author":"S Agewall","year":"2017","unstructured":"Agewall, S. Anticoagulation, atherosclerosis, and heart failure. Eur. Hear. J. Cardiovasc. Pharmacother. 3, 1\u20132 (2017).","journal-title":"Eur. Hear. J. Cardiovasc. Pharmacother."},{"key":"1037_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1161\/ATVBAHA.119.312142","volume":"40","author":"GH Bevan","year":"2020","unstructured":"Bevan, G. H. & Solaru, K. T. W. Evidence-based medical management of peripheral artery disease. Arterioscler. Thromb. Vasc. Biol. 40, 541\u2013553 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR10","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.2174\/1381612826666200427084949","volume":"26","author":"D Sarmah","year":"2020","unstructured":"Sarmah, D. et al. The role of inflammasomes in atherosclerosis and stroke pathogenesis. Curr. Pharm. Des. 26, 4234\u20134245 (2020).","journal-title":"Curr. Pharm. Des."},{"key":"1037_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/jamaneurol.2021.5080","volume":"79","author":"S Koton","year":"2022","unstructured":"Koton, S. et al. Association of ischemic stroke incidence, severity, and recurrence with dementia in the atherosclerosis risk in communities cohort study. JAMA Neurol. 79, 271\u2013280 (2022).","journal-title":"JAMA Neurol."},{"key":"1037_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature10146","volume":"473","author":"P Libby","year":"2011","unstructured":"Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317\u2013325 (2011).","journal-title":"Nature"},{"key":"1037_CR13","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V. & Roth, G. A. The global burden of cardiovascular diseases and risk a compass for future health. J. Am. Coll. Cardiol. 80, 2361\u20132371 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1037_CR14","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1161\/CIR.0000000000000450","volume":"134","author":"B Bozkurt","year":"2016","unstructured":"Bozkurt, B. et al. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation 134, e535\u2013e578 (2016).","journal-title":"Circulation"},{"key":"1037_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11010-021-04307-x","volume":"477","author":"D Dasagrandhi","year":"2022","unstructured":"Dasagrandhi, D., Muthuswamy, A. & Swaminathan, J. K. Atherosclerosis: nexus of vascular dynamics and cellular cross talks. Mol. Cell Biochem. 477, 571\u2013584 (2022).","journal-title":"Mol. Cell Biochem."},{"key":"1037_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090201","volume":"9","author":"C-L Huang","year":"2014","unstructured":"Huang, C.-L. et al. Association of lower extremity arterial calcification with amputation and mortality in patients with symptomatic peripheral artery disease. PLoS ONE 9, e90201 (2014).","journal-title":"PLoS ONE"},{"key":"1037_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/01.ATV.0000148548.47755.22","volume":"25","author":"J Liu","year":"2005","unstructured":"Liu, J. et al. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 25, 174\u2013179 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.acvd.2023.07.007","volume":"116","author":"L Rochette","year":"2023","unstructured":"Rochette, L. et al. Interplay between efferocytosis and atherosclerosis. Arch. Cardiovasc. Dis. 116, 474\u2013484 (2023).","journal-title":"Arch. Cardiovasc. Dis."},{"key":"1037_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/oxfordjournals.bmb.a011626","volume":"53","author":"J Savill","year":"1997","unstructured":"Savill, J. Recognition and phagocytosis of cells undergoing apoptosis. Br. Med. Bull. 53, 491\u2013508 (1997).","journal-title":"Br. Med. Bull."},{"key":"1037_CR20","doi-asserted-by":"publisher","first-page":"R795","DOI":"10.1016\/S0960-9822(01)00474-2","volume":"11","author":"PM Henson","year":"2001","unstructured":"Henson, P. M., Bratton, D. L. & Fadok, V. A. Apoptotic cell removal. Curr. Biol. 11, R795\u2013R805 (2001).","journal-title":"Curr. Biol."},{"key":"1037_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.immuni.2019.04.018","volume":"50","author":"S Morioka","year":"2019","unstructured":"Morioka, S., Mauer\u00f6der, C. & Ravichandran, K. S. Living on the edge: efferocytosis at the interface of homeostasis and pathology. Immunity 50, 1149\u20131162 (2019).","journal-title":"Immunity"},{"key":"1037_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.omto.2020.04.010","volume":"17","author":"D Lin","year":"2020","unstructured":"Lin, D. et al. Efferocytosis and its associated cytokines: a light on non-tumor and tumor diseases? Mol. Ther. - Oncolytics 17, 394\u2013407 (2020).","journal-title":"Mol. Ther. - Oncolytics"},{"key":"1037_CR23","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s10495-010-0516-6","volume":"15","author":"EB Thorp","year":"2010","unstructured":"Thorp, E. B. Mechanisms of failed apoptotic cell clearance by phagocyte subsets in cardiovascular disease. Apoptosis 15, 1124\u20131136 (2010).","journal-title":"Apoptosis"},{"key":"1037_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41418-019-0370-1","volume":"27","author":"BD Gerlach","year":"2020","unstructured":"Gerlach, B. D. et al. Resolvin D1 promotes the targeting and clearance of necroptotic cells. Cell Death Differ. 27, 525\u2013539 (2020).","journal-title":"Cell Death Differ."},{"key":"1037_CR25","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.cmet.2021.10.015","volume":"33","author":"BD Gerlach","year":"2021","unstructured":"Gerlach, B. D. et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab. 33, 2445\u20132463.e8 (2021).","journal-title":"Cell Metab."},{"key":"1037_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41573-022-00470-y","volume":"21","author":"P Mehrotra","year":"2022","unstructured":"Mehrotra, P. & Ravichandran, K. S. Drugging the efferocytosis process: concepts and opportunities. Nat. Rev. Drug. Discov. 21, 601\u2013620 (2022).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1037_CR27","doi-asserted-by":"publisher","first-page":"107919","DOI":"10.1016\/j.pharmthera.2021.107919","volume":"229","author":"JTO Cabrera","year":"2022","unstructured":"Cabrera, J. T. O. & Makino, A. Efferocytosis of vascular cells in cardiovascular disease. Pharmacol. Ther. 229, 107919 (2022).","journal-title":"Pharmacol. Ther."},{"key":"1037_CR28","doi-asserted-by":"publisher","first-page":"15818","DOI":"10.1073\/pnas.2006348117","volume":"117","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade. Proc. Natl Acad. Sci. USA 117, 15818\u201315826 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1037_CR29","doi-asserted-by":"publisher","first-page":"599415","DOI":"10.3389\/fimmu.2020.599415","volume":"11","author":"V Sorokin","year":"2020","unstructured":"Sorokin, V. et al. Role of vascular smooth muscle cell plasticity and interactions in vessel wall inflammation. Front. Immunol. 11, 599415 (2020).","journal-title":"Front. Immunol."},{"key":"1037_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nrm1244","volume":"4","author":"AI Tauber","year":"2003","unstructured":"Tauber, A. I. Metchnikoff and the phagocytosis theory. Nat. Rev. Mol. Cell Biol. 4, 897\u2013901 (2003).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1037_CR31","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.4049\/jimmunol.148.7.2207","volume":"148","author":"VA Fadok","year":"1992","unstructured":"Fadok, V. A. et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148, 2207\u20132216 (1992).","journal-title":"J. Immunol."},{"key":"1037_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1074-7613(00)80410-0","volume":"4","author":"NC Franc","year":"1996","unstructured":"Franc, N. C., Dimarcq, J.-L., Lagueux, M., Hoffmann, J. & Ezekowitz, R. A. B. Croquemort, a novel Drosophila hemocyte\/macrophage receptor that recognizes apoptotic cells. Immunity 4, 431\u2013443 (1996).","journal-title":"Immunity"},{"key":"1037_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1242\/dev.117.1.29","volume":"117","author":"JM Abrams","year":"1993","unstructured":"Abrams, J. M., White, K., Fessler, L. I. & Steller, H. Programmed cell death during Drosophila embryogenesis. Development 117, 29\u201343 (1993).","journal-title":"Development"},{"key":"1037_CR34","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1126\/science.8171319","volume":"264","author":"K White","year":"1994","unstructured":"White, K. et al. Genetic control of programmed cell death in Drosophila. Science 264, 677\u2013683 (1994).","journal-title":"Science"},{"key":"1037_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/genetics\/129.1.79","volume":"129","author":"RE Ellis","year":"1991","unstructured":"Ellis, R. E., Jacobson, D. M. & Horvitz, H. R. Genes required for the engulfment of cell corpses during programmed cell death in Caenorhabditis elegans. Genetics 129, 79\u201394 (1991).","journal-title":"Genetics"},{"key":"1037_CR36","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00018-016-2196-z","volume":"73","author":"X Wang","year":"2016","unstructured":"Wang, X. & Yang, C. Programmed cell death and clearance of cell corpses in Caenorhabditis elegans. Cell. Mol. Life Sci. 73, 2221\u20132236 (2016).","journal-title":"Cell. Mol. Life Sci."},{"key":"1037_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35604-8","volume":"13","author":"J Shi","year":"2022","unstructured":"Shi, J. et al. A genome-wide CRISPR screen identifies WDFY3 as a regulator of macrophage efferocytosis. Nat. Commun. 13, 7929 (2022).","journal-title":"Nat. Commun."},{"key":"1037_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-021-03879-4","volume":"597","author":"RA Kamber","year":"2021","unstructured":"Kamber, R. A. et al. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature 597, 549\u2013554 (2021).","journal-title":"Nature"},{"key":"1037_CR39","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/s41588-018-0254-1","volume":"7","author":"MS Haney","year":"2018","unstructured":"Haney, M. S. et al. Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens. Nat. Genet. 7, 1716\u20131727 (2018).","journal-title":"Nat. Genet."},{"key":"1037_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang, D., Chen, X., Kang, R. & Kroemer, G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 31, 107\u2013125 (2021).","journal-title":"Cell Res."},{"key":"1037_CR41","doi-asserted-by":"publisher","first-page":"109098","DOI":"10.1016\/j.abb.2021.109098","volume":"715","author":"X Lin","year":"2022","unstructured":"Lin, X. et al. Focus on ferroptosis, pyroptosis, apoptosis and autophagy of vascular endothelial cells to the strategic targets for the treatment of atherosclerosis. Arch. Biochem. Biophys. 715, 109098 (2022).","journal-title":"Arch. Biochem. Biophys."},{"key":"1037_CR42","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1161\/ATVBAHA.122.318177","volume":"42","author":"P Puylaert","year":"2022","unstructured":"Puylaert, P., Zurek, M., Rayner, K. J., Meyer, G. R. Y. D. & Martinet, W. Regulated necrosis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 42, 1283\u20131306 (2022).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR43","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","volume":"18","author":"D Bertheloot","year":"2021","unstructured":"Bertheloot, D., Latz, E. & Franklin, B. S. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death. Cell. Mol. Immunol. 18, 1106\u20131121 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"1037_CR44","doi-asserted-by":"publisher","first-page":"101781","DOI":"10.1016\/j.smim.2023.101781","volume":"69","author":"SO Vasudevan","year":"2023","unstructured":"Vasudevan, S. O., Behl, B. & Rathinam, V. A. Pyroptosis-induced inflammation and tissue damage. Semin. Immunol. 69, 101781 (2023).","journal-title":"Semin. Immunol."},{"key":"1037_CR45","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/cdd.2009.184","volume":"17","author":"TV Berghe","year":"2010","unstructured":"Berghe, T. V. et al. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ. 17, 922\u2013930 (2010).","journal-title":"Cell Death Differ."},{"key":"1037_CR46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1161\/CIRCULATIONAHA.116.025684","volume":"135","author":"Y Kojima","year":"2017","unstructured":"Kojima, Y., Weissman, I. L. & Leeper, N. J. The role of efferocytosis in atherosclerosis. Circulation 135, 476\u2013489 (2017).","journal-title":"Circulation"},{"key":"1037_CR47","doi-asserted-by":"publisher","first-page":"114830","DOI":"10.1016\/j.biopha.2023.114830","volume":"163","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease. Biomed. Pharmacother. 163, 114830 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"1037_CR48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/bjc.1972.33","volume":"26","author":"JFR Kerr","year":"1972","unstructured":"Kerr, J. F. R., Wyllie, A. H. & Currie, A. R. Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. Br. J. Cancer 26, 239\u2013257 (1972).","journal-title":"Br. J. Cancer"},{"key":"1037_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood.V81.1.143.143","volume":"81","author":"LE Robertson","year":"1993","unstructured":"Robertson, L. E. et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2\u2032-deoxyadenosine and 9-\u03b2-D-arabinosyl-2-fluoroadenine. Blood 81, 143\u2013150 (1993).","journal-title":"Blood"},{"key":"1037_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/35011084","volume":"405","author":"VA Fadok","year":"2000","unstructured":"Fadok, V. A. et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405, 85\u201390 (2000).","journal-title":"Nature"},{"key":"1037_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1388-1981(99)00110-9","volume":"1439","author":"EM Bevers","year":"1999","unstructured":"Bevers, E. M., Comfurius, P., Dekkers, D. W. C. & Zwaal, R. F. A. Lipid translocation across the plasma membrane of mammalian cells. Biochim. Biophys. Acta 1439, 317\u2013330 (1999).","journal-title":"Biochim. Biophys. Acta"},{"key":"1037_CR52","doi-asserted-by":"publisher","first-page":"S206","DOI":"10.1007\/BF01644035","volume":"19","author":"B Roelofsen","year":"1991","unstructured":"Roelofsen, B. Molecular architecture and dynamics of the plasma membrane lipid bilayer: the red blood cell as a model. Infection 19, S206\u2013S209 (1991).","journal-title":"Infection"},{"key":"1037_CR53","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1126\/science.1252809","volume":"344","author":"K Segawa","year":"2014","unstructured":"Segawa, K. et al. Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science 344, 1164\u20131168 (2014).","journal-title":"Science"},{"key":"1037_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41569-019-0239-5","volume":"17","author":"C Souilhol","year":"2020","unstructured":"Souilhol, C. et al. Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes. Nat. Rev. Cardiol. 17, 52\u201363 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"1037_CR55","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/eurheartj\/ehad373","volume":"44","author":"K Kaw","year":"2023","unstructured":"Kaw, K. et al. Smooth muscle \u03b1-actin missense variant promotes atherosclerosis through modulation of intracellular cholesterol in smooth muscle cells. Eur. Hear. J. 44, 2713\u20132726 (2023).","journal-title":"Eur. Hear. J."},{"key":"1037_CR56","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11883-017-0678-6","volume":"19","author":"AJ Kattoor","year":"2017","unstructured":"Kattoor, A. J., Pothineni, N. V. K., Palagiri, D. & Mehta, J. L. Oxidative stress in atherosclerosis. Curr. Atheroscler. Rep. 19, 42 (2017).","journal-title":"Curr. Atheroscler. Rep."},{"key":"1037_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tcm.2018.05.010","volume":"29","author":"A Hartley","year":"2019","unstructured":"Hartley, A., Haskard, D. & Khamis, R. Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis \u2013 novel insights and future directions in diagnosis and therapy. Trends Cardiovasc. Med. 29, 22\u201326 (2019).","journal-title":"Trends Cardiovasc. Med."},{"key":"1037_CR58","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1037_CR59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jjcc.2018.05.010","volume":"73","author":"J Moriya","year":"2019","unstructured":"Moriya, J. Critical roles of inflammation in atherosclerosis. J. Cardiol. 73, 22\u201327 (2019).","journal-title":"J. Cardiol."},{"key":"1037_CR60","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0002-9440(10)64641-X","volume":"157","author":"FD Kolodgie","year":"2000","unstructured":"Kolodgie, F. D. et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am. J. Pathol. 157, 1259\u20131268 (2000).","journal-title":"Am. J. Pathol."},{"key":"1037_CR61","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cmet.2009.03.003","volume":"9","author":"E Thorp","year":"2009","unstructured":"Thorp, E. et al. Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe\u2212\/\u2212 and Ldlr\u2212\/\u2212 mice lacking CHOP. Cell Metab. 9, 474\u2013481 (2009).","journal-title":"Cell Metab."},{"key":"1037_CR62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1161\/ATVBAHA.108.176495","volume":"29","author":"E Thorp","year":"2009","unstructured":"Thorp, E. et al. Brief report: increased apoptosis in advanced atherosclerotic lesions of Apoe\u2212\/\u2212 mice lacking macrophage Bcl-2. Arterioscler. Thromb. Vasc. Biol. 29, 169\u2013172 (2009).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR63","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cmet.2005.02.002","volume":"1","author":"S Arai","year":"2005","unstructured":"Arai, S. et al. A role for the apoptosis inhibitory factor AIM\/Sp\u03b1\/Api6 in atherosclerosis development. Cell Metab. 1, 201\u2013213 (2005).","journal-title":"Cell Metab."},{"key":"1037_CR64","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.108.806158","volume":"119","author":"EL Gautier","year":"2009","unstructured":"Gautier, E. L. et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 119, 1795\u20131804 (2009).","journal-title":"Circulation"},{"key":"1037_CR65","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nature15541","volume":"526","author":"N Kayagaki","year":"2015","unstructured":"Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666\u2013671 (2015).","journal-title":"Nature"},{"key":"1037_CR66","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660\u2013665 (2015).","journal-title":"Nature"},{"key":"1037_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0257-3","volume":"9","author":"X Wu","year":"2018","unstructured":"Wu, X. et al. Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. Cell Death Dis. 9, 171 (2018).","journal-title":"Cell Death Dis."},{"key":"1037_CR68","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41586-021-03341-5","volume":"592","author":"TP Fidler","year":"2021","unstructured":"Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592, 296\u2013301 (2021).","journal-title":"Nature"},{"key":"1037_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2064-5","volume":"10","author":"E Park","year":"2019","unstructured":"Park, E. & Chung, S. W. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. Cell Death Dis. 10, 822 (2019).","journal-title":"Cell Death Dis."},{"key":"1037_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14128","volume":"8","author":"C Rogers","year":"2017","unstructured":"Rogers, C. et al. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic\/pyroptotic cell death. Nat. Commun. 8, 14128 (2017).","journal-title":"Nat. Commun."},{"key":"1037_CR71","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1091\/mbc.e03-09-0668","volume":"15","author":"G Brouckaert","year":"2004","unstructured":"Brouckaert, G. et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol. Biol. Cell 15, 1089\u20131100 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"1037_CR72","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1097\/CCM.0b013e3181a001ae","volume":"37","author":"ED Crouser","year":"2009","unstructured":"Crouser, E. D. et al. Monocyte activation by necrotic cells is promoted by mitochondrial proteins and formyl peptide receptors. Crit. Care Med. 37, 2000\u20132009 (2009).","journal-title":"Crit. Care Med."},{"key":"1037_CR73","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/imr.12212","volume":"262","author":"SA Freeman","year":"2014","unstructured":"Freeman, S. A. & Grinstein, S. Phagocytosis: receptors, signal integration, and the cytoskeleton. Immunol. Rev. 262, 193\u2013215 (2014).","journal-title":"Immunol. Rev."},{"key":"1037_CR74","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0092-8674(00)80438-9","volume":"91","author":"T Imai","year":"1997","unstructured":"Imai, T. et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91, 521\u2013530 (1997).","journal-title":"Cell"},{"key":"1037_CR75","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1182\/blood-2008-06-162404","volume":"112","author":"LA Truman","year":"2008","unstructured":"Truman, L. A. et al. CX3CL1\/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 112, 5026\u20135036 (2008).","journal-title":"Blood"},{"key":"1037_CR76","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1172\/JCI15555","volume":"111","author":"P Lesnik","year":"2003","unstructured":"Lesnik, P., Haskell, C. A. & Charo, I. F. Decreased atherosclerosis in CX3CR1\u2212\/\u2212 mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111, 333\u2013340 (2003).","journal-title":"J. Clin. Invest."},{"key":"1037_CR77","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64787","volume":"10","author":"AK Narahari","year":"2021","unstructured":"Narahari, A. K. et al. ATP and large signaling metabolites flux through caspase-activated pannexin 1 channels. eLife 10, e64787 (2021).","journal-title":"eLife"},{"key":"1037_CR78","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.pharmthera.2005.04.013","volume":"112","author":"MJL Bours","year":"2006","unstructured":"Bours, M. J. L., Swennen, E. L. R., Virgilio, F. D., Cronstein, B. N. & Dagnelie, P. C. Adenosine 5\u2032-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112, 358\u2013404 (2006).","journal-title":"Pharmacol. Ther."},{"key":"1037_CR79","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nri2938","volume":"11","author":"WG Junger","year":"2011","unstructured":"Junger, W. G. Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 11, 201\u2013212 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"1037_CR80","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/wmts.62","volume":"1","author":"L Erb","year":"2012","unstructured":"Erb, L. & Weisman, G. A. Coupling of P2Y receptors to G proteins and other signaling pathways. Wiley Interdiscip. Rev. Membr. Transp. Signal. 1, 789\u2013803 (2012).","journal-title":"Wiley Interdiscip. Rev. Membr. Transp. Signal."},{"key":"1037_CR81","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nature08296","volume":"461","author":"MR Elliott","year":"2009","unstructured":"Elliott, M. R. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282\u2013286 (2009).","journal-title":"Nature"},{"key":"1037_CR82","doi-asserted-by":"publisher","first-page":"jcs260364","DOI":"10.1242\/jcs.260364","volume":"135","author":"F Kage","year":"2022","unstructured":"Kage, F. et al. Lamellipodia-like actin networks in cells lacking WAVE regulatory complex. J. Cell Sci. 135, jcs260364 (2022).","journal-title":"J. Cell Sci."},{"key":"1037_CR83","doi-asserted-by":"publisher","first-page":"ra55","DOI":"10.1126\/scisignal.2000588","volume":"3","author":"M Kronlage","year":"2010","unstructured":"Kronlage, M. et al. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci. Signal. 3, ra55 (2010).","journal-title":"Sci. Signal."},{"key":"1037_CR84","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11302-013-9374-3","volume":"9","author":"E Hochhauser","year":"2013","unstructured":"Hochhauser, E. et al. P2Y2 receptor agonist with enhanced stability protects the heart from ischemic damage in vitro and in vivo. Purinergic Signal. 9, 633\u2013642 (2013).","journal-title":"Purinergic Signal."},{"key":"1037_CR85","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1161\/ATVBAHA.116.308561","volume":"37","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Endothelial cell-specific deletion of P2Y2 receptor promotes plaque stability in atherosclerosis-susceptible ApoE-null mice. Arterioscler. Thromb. Vasc. Biol. 37, 75\u201383 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR86","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.it.2018.08.005","volume":"39","author":"E Wei\u00df","year":"2018","unstructured":"Wei\u00df, E. & Kretschmer, D. Formyl-peptide receptors in infection, inflammation, and cancer. Trends Immunol. 39, 815\u2013829 (2018).","journal-title":"Trends Immunol."},{"key":"1037_CR87","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1126\/science.1195491","volume":"330","author":"B McDonald","year":"2010","unstructured":"McDonald, B. et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330, 362\u2013366 (2010).","journal-title":"Science"},{"key":"1037_CR88","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature10632","volume":"480","author":"SK Yoo","year":"2011","unstructured":"Yoo, S. K., Starnes, T. W., Deng, Q. & Huttenlocher, A. Lyn is a redox sensor that mediates leukocyte wound attraction in vivo. Nature 480, 109\u2013112 (2011).","journal-title":"Nature"},{"key":"1037_CR89","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/1753425908093932","volume":"14","author":"N Nakao","year":"2008","unstructured":"Nakao, N. et al. Hydrogen peroxide induces the production of tumor necrosis factor-\u03b1 in RAW 264.7 macrophage cells via activation of p38 and stress-activated protein kinase. Innate Immun. 14, 190\u2013196 (2008).","journal-title":"Innate Immun."},{"key":"1037_CR90","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nature09413","volume":"467","author":"FB Chekeni","year":"2010","unstructured":"Chekeni, F. B. et al. Pannexin 1 channels mediate \u2018find-me\u2019 signal release and membrane permeability during apoptosis. Nature 467, 863\u2013867 (2010).","journal-title":"Nature"},{"key":"1037_CR91","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.devcel.2016.06.029","volume":"38","author":"MR Elliott","year":"2016","unstructured":"Elliott, M. R. & Ravichandran, K. S. The dynamics of apoptotic cell clearance. Dev. Cell 38, 147\u2013160 (2016).","journal-title":"Dev. Cell"},{"key":"1037_CR92","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.tips.2007.07.002","volume":"28","author":"FD Virgilio","year":"2007","unstructured":"Virgilio, F. D. Liaisons dangereuses: P2X7 and the inflammasome. Trends Pharmacol. Sci. 28, 465\u2013472 (2007).","journal-title":"Trends Pharmacol. Sci."},{"key":"1037_CR93","doi-asserted-by":"publisher","first-page":"20388","DOI":"10.1073\/pnas.0908698106","volume":"106","author":"SS Iyer","year":"2009","unstructured":"Iyer, S. S. et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl Acad. Sci. USA 106, 20388\u201320393 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1037_CR94","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/aps.2013.8","volume":"34","author":"M Liu","year":"2013","unstructured":"Liu, M. et al. Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE\u2212\/\u2212 mice by downregulating the HMGB1-RAGE axis. Acta Pharmacol. Sin. 34, 830\u2013836 (2013).","journal-title":"Acta Pharmacol. Sin."},{"key":"1037_CR95","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2013.09.010","volume":"231","author":"Y Hirata","year":"2013","unstructured":"Hirata, Y. et al. HMGB1 plays a critical role in vascular inflammation and lesion formation via toll-like receptor 9. Atherosclerosis 231, 227\u2013233 (2013).","journal-title":"Atherosclerosis"},{"key":"1037_CR96","doi-asserted-by":"publisher","first-page":"111555","DOI":"10.1016\/j.biopha.2021.111555","volume":"139","author":"A Wahid","year":"2021","unstructured":"Wahid, A., Chen, W., Wang, X. & Tang, X. High-mobility group Box 1 serves as an inflammation driver of cardiovascular disease. Biomed. Pharmacother. 139, 111555 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"1037_CR97","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature00858","volume":"418","author":"P Scaffidi","year":"2002","unstructured":"Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191\u2013195 (2002).","journal-title":"Nature"},{"key":"1037_CR98","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.numecd.2022.05.007","volume":"32","author":"H Fan","year":"2022","unstructured":"Fan, H. et al. Association between plasma growth arrest-specific protein 6 and carotid atherosclerosis in type 2 diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 32, 1917\u20131923 (2022).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"1037_CR99","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1161\/ATVBAHA.108.169078","volume":"28","author":"H Ait-Oufella","year":"2008","unstructured":"Ait-Oufella, H. et al. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28, 1429\u20131431 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR100","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/ATVBAHA.108.167197","volume":"28","author":"E Thorp","year":"2008","unstructured":"Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G. & Tabas, I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of Apoe\u2212\/\u2212 mice. Arterioscler. Thromb. Vasc. Biol. 28, 1421\u20131428 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR101","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.1073\/pnas.1524292113","volume":"113","author":"B Cai","year":"2016","unstructured":"Cai, B. et al. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc. Natl Acad. Sci. USA 113, 6526\u20136531 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1037_CR102","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1172\/JCI90520","volume":"127","author":"B Cai","year":"2017","unstructured":"Cai, B. et al. MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J. Clin. Invest. 127, 564\u2013568 (2017).","journal-title":"J. Clin. Invest."},{"key":"1037_CR103","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1248\/cpb.c21-00701","volume":"69","author":"H Tateishi","year":"2021","unstructured":"Tateishi, H. et al. A new inhibitor of ADAM17 composed of a zinc-binding dithiol moiety and a specificity pocket-binding appendage. Chem. Pharm. Bull. 69, 1123\u20131130 (2021).","journal-title":"Chem. Pharm. Bull."},{"key":"1037_CR104","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/ATVBAHA.109.202051","volume":"30","author":"PG Yancey","year":"2010","unstructured":"Yancey, P. G. et al. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler. Thromb. Vasc. Biol. 30, 787\u2013795 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR105","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/s41591-022-01891-3","volume":"28","author":"C Tcheandjieu","year":"2022","unstructured":"Tcheandjieu, C. et al. Large-scale genome-wide association study of coronary artery disease in genetically diverse populations. Nat. Med. 28, 1679\u20131692 (2022).","journal-title":"Nat. Med."},{"key":"1037_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064145","volume":"8","author":"M Canuel","year":"2013","unstructured":"Canuel, M. et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS ONE 8, e64145 (2013).","journal-title":"PLoS ONE"},{"key":"1037_CR107","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.7150\/thno.83914","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu, S. et al. PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging. Theranostics 13, 2914\u20132929 (2023).","journal-title":"Theranostics"},{"key":"1037_CR108","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1172\/JCI70391","volume":"124","author":"Y Kojima","year":"2014","unstructured":"Kojima, Y. et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J. Clin. Invest. 124, 1083\u20131097 (2014).","journal-title":"J. Clin. Invest."},{"key":"1037_CR109","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.3390\/cells10123598","volume":"10","author":"V Anandan","year":"2021","unstructured":"Anandan, V. et al. Cyclophilin A impairs efferocytosis and accelerates atherosclerosis by overexpressing CD 47 and down-regulating calreticulin. Cells 10, 3598 (2021).","journal-title":"Cells"},{"key":"1037_CR110","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41588-022-01233-6","volume":"54","author":"KG Aragam","year":"2022","unstructured":"Aragam, K. G. et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat. Genet. 54, 1803\u20131815 (2022).","journal-title":"Nat. Genet."},{"key":"1037_CR111","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1161\/CIRCULATIONAHA.106.662080","volume":"115","author":"H Ait-Oufella","year":"2007","unstructured":"Ait-Oufella, H. et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation 115, 2168\u20132177 (2007).","journal-title":"Circulation"},{"key":"1037_CR112","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1161\/ATVBAHA.122.317049","volume":"42","author":"K-U Jarr","year":"2022","unstructured":"Jarr, K.-U., Kojima, Y., Weissman, I. L. & Leeper, N. J. 2021 Jeffrey M. Hoeg Award lecture: defining the role of efferocytosis in cardiovascular disease: a focus on the CD47 (cluster of differentiation 47) axis. Arterioscler. Thromb. Vasc. Biol. 42, e145\u2013e154 (2022).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR113","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA 109, 6662\u20136667 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1037_CR114","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nature18935","volume":"536","author":"Y Kojima","year":"2016","unstructured":"Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86\u201390 (2016).","journal-title":"Nature"},{"key":"1037_CR115","first-page":"179","volume":"3","author":"S Kaur","year":"2020","unstructured":"Kaur, S., Cicalese, K. V., Banerjee, R. & Roberts, D. D. Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment. Antib. Ther. 3, 179\u2013192 (2020).","journal-title":"Antib. Ther."},{"key":"1037_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.7","volume":"7","author":"EC Pietsch","year":"2017","unstructured":"Pietsch, E. C. et al. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J. 7, e536 (2017).","journal-title":"Blood Cancer J."},{"key":"1037_CR117","unstructured":"Gilead. Gilead statement on discontinuation of phase 3 ENHANCE-3 study in AML (Gilead, 2024)."},{"key":"1037_CR118","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1200\/JCO.22.02604","volume":"41","author":"NG Daver","year":"2023","unstructured":"Daver, N. G. et al. Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results. J. Clin. Oncol. 41, 4893\u20134904 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1037_CR119","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1056\/NEJMc2029834","volume":"384","author":"K-U Jarr","year":"2021","unstructured":"Jarr, K.-U. et al. Effect of CD47 blockade on vascular inflammation. N. Engl. J. Med. 384, 382\u2013383 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1037_CR120","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1161\/ATVBAHA.120.315239","volume":"40","author":"K-U Jarr","year":"2020","unstructured":"Jarr, K.-U. et al. 18F-fluorodeoxyglucose-positron emission tomography imaging detects response to therapeutic intervention and plaque vulnerability in a murine model of advanced atherosclerotic disease \u2013 brief report. Arterioscler. Thromb. Vasc. Biol. 40, 2821\u20132828 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR121","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1093\/cvr\/cvab369","volume":"118","author":"B Singla","year":"2021","unstructured":"Singla, B. et al. Loss of myeloid cell-specific SIRP\u03b1, but not CD47, attenuates inflammation and suppresses atherosclerosis. Cardiovasc. Res. 118, 3097\u20133111 (2021).","journal-title":"Cardiovasc. Res."},{"key":"1037_CR122","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1083\/jcb.200708043","volume":"180","author":"RK Tsai","year":"2008","unstructured":"Tsai, R. K. & Discher, D. E. Inhibition of \u201cself\u201d engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J. Cell Biol. 180, 989\u20131003 (2008).","journal-title":"J. Cell Biol."},{"key":"1037_CR123","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41565-019-0619-3","volume":"15","author":"AM Flores","year":"2020","unstructured":"Flores, A. M. et al. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis. Nat. Nanotechnol. 15, 154\u2013161 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1037_CR124","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/ATVBAHA.118.311569","volume":"39","author":"AM Flores","year":"2019","unstructured":"Flores, A. M. et al. Nanoparticle therapy for vascular diseases. Arterioscler. Thromb. Vasc. Biol. 39, 635\u2013646 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR125","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cmet.2022.07.005","volume":"34","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder. Cell Metab. 34, 1088\u20131103.e6 (2022).","journal-title":"Cell Metab."},{"key":"1037_CR126","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nature00811","volume":"418","author":"S Brown","year":"2002","unstructured":"Brown, S. et al. Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment. Nature 418, 200\u2013203 (2002).","journal-title":"Nature"},{"key":"1037_CR127","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12929-020-00698-z","volume":"28","author":"Y-W Hsu","year":"2021","unstructured":"Hsu, Y.-W. et al. Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation. J. Biomed. Sci. 28, 5 (2021).","journal-title":"J. Biomed. Sci."},{"key":"1037_CR128","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","volume":"19","author":"AA Barkal","year":"2018","unstructured":"Barkal, A. A. et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat. Immunol. 19, 76\u201384 (2018).","journal-title":"Nat. Immunol."},{"key":"1037_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19334-x","volume":"12","author":"T Sinthuwiwat","year":"2022","unstructured":"Sinthuwiwat, T. et al. A LILRB1 variant with a decreased ability to phosphorylate SHP-1 leads to autoimmune diseases. Sci. Rep. 12, 15420 (2022).","journal-title":"Sci. Rep."},{"key":"1037_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18298-8","volume":"11","author":"DH Peng","year":"2020","unstructured":"Peng, D. H. et al. Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat. Commun. 11, 4520 (2020).","journal-title":"Nat. Commun."},{"key":"1037_CR131","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/imr.12218","volume":"262","author":"S Colin","year":"2014","unstructured":"Colin, S., Chinetti\u2010Gbaguidi, G. & Staels, B. Macrophage phenotypes in atherosclerosis. Immunol. Rev. 262, 153\u2013166 (2014).","journal-title":"Immunol. Rev."},{"key":"1037_CR132","doi-asserted-by":"publisher","DOI":"10.1097\/IN9.0000000000000017","volume":"5","author":"D Kumar","year":"2023","unstructured":"Kumar, D., Pandit, R. & Yurdagul, A. Mechanisms of continual efferocytosis by macrophages and its role in mitigating atherosclerosis. Immunometabolism 5, e00017 (2023).","journal-title":"Immunometabolism"},{"key":"1037_CR133","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1182\/blood-2005-10-4144","volume":"107","author":"W Xu","year":"2006","unstructured":"Xu, W. et al. IL-10-producing macrophages preferentially clear early apoptotic cells. Blood 107, 4930\u20134937 (2006).","journal-title":"Blood"},{"key":"1037_CR134","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.cmet.2020.01.001","volume":"31","author":"A Yurdagul","year":"2020","unstructured":"Yurdagul, A. et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 31, 518\u2013533.e10 (2020).","journal-title":"Cell Metab."},{"key":"1037_CR135","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1084\/jem.20012094","volume":"196","author":"PL Cohen","year":"2002","unstructured":"Cohen, P. L. et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J. Exp. Med. 196, 135\u2013140 (2002).","journal-title":"J. Exp. Med."},{"key":"1037_CR136","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1189\/jlb.0611289","volume":"91","author":"Y Lee","year":"2012","unstructured":"Lee, Y. et al. Inhibiting Mer receptor tyrosine kinase suppresses STAT1, SOCS1\/3, and NF\u2010\u03baB activation and enhances inflammatory responses in lipopolysaccharide\u2010induced acute lung injury. J. Leukoc. Biol. 91, 921\u2013932 (2012).","journal-title":"J. Leukoc. Biol."},{"key":"1037_CR137","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1124\/jpet.112.199778","volume":"344","author":"J-Y Choi","year":"2013","unstructured":"Choi, J.-Y. et al. Upregulation of mer receptor tyrosine kinase signaling attenuated lipopolysaccharide-induced lung inflammation. J. Pharmacol. Exp. Ther. 344, 447\u2013458 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1037_CR138","doi-asserted-by":"publisher","first-page":"ra21","DOI":"10.1126\/scisignal.2005864","volume":"8","author":"J-Y Choi","year":"2015","unstructured":"Choi, J.-Y. et al. Mer signaling increases the abundance of the transcription factor LXR to promote the resolution of acute sterile inflammation. Sci. Signal. 8, ra21 (2015).","journal-title":"Sci. Signal."},{"key":"1037_CR139","doi-asserted-by":"publisher","first-page":"eaar3721","DOI":"10.1126\/scisignal.aar3721","volume":"11","author":"B Cai","year":"2018","unstructured":"Cai, B. et al. MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity. Sci. Signal. 11, eaar3721 (2018).","journal-title":"Sci. Signal."},{"key":"1037_CR140","doi-asserted-by":"publisher","first-page":"115075","DOI":"10.1016\/j.bcp.2022.115075","volume":"201","author":"M Bardin","year":"2022","unstructured":"Bardin, M. et al. The resolvin D2\u2013GPR18 axis is expressed in human coronary atherosclerosis and transduces atheroprotection in apolipoprotein E deficient mice. Biochem. Pharmacol. 201, 115075 (2022).","journal-title":"Biochem. Pharmacol."},{"key":"1037_CR141","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2016.05.001","volume":"250","author":"K Salic","year":"2016","unstructured":"Salic, K. et al. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 250, 158\u2013165 (2016).","journal-title":"Atherosclerosis"},{"key":"1037_CR142","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1161\/ATVBAHA.115.305324","volume":"35","author":"H Hasturk","year":"2018","unstructured":"Hasturk, H. et al. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler. Thromb. Vasc. Biol. 35, 1123\u20131133 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR143","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/1753425920975082","volume":"27","author":"S Polumuri","year":"2020","unstructured":"Polumuri, S., Perkins, D. J. & Vogel, S. N. cAMP levels regulate macrophage alternative activation marker expression. Innate Immun. 27, 133\u2013142 (2020).","journal-title":"Innate Immun."},{"key":"1037_CR144","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1111\/jcmm.15436","volume":"24","author":"K Shan","year":"2020","unstructured":"Shan, K. et al. Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization. J. Cell. Mol. Med. 24, 8045\u20138056 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"1037_CR145","doi-asserted-by":"publisher","first-page":"106781","DOI":"10.1016\/j.prostaglandins.2023.106781","volume":"169","author":"M Molaie","year":"2023","unstructured":"Molaie, M. et al. Imbalanced serum levels of resolvin E1 (RvE1) and leukotriene B4 (LTB4) may contribute to the pathogenesis of atherosclerosis. Prostaglandins Other Lipid Mediat. 169, 106781 (2023).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"1037_CR146","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cmet.2018.12.004","volume":"29","author":"S Zhang","year":"2019","unstructured":"Zhang, S. et al. Efferocytosis fuels requirements of fatty acid oxidation and the electron transport chain to polarize macrophages for tissue repair. Cell Metab. 29, 443\u2013456.e5 (2019).","journal-title":"Cell Metab."},{"key":"1037_CR147","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2018","unstructured":"Bhatt, D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 380, 11\u201322 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1037_CR148","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamacardio.2022.3698","volume":"7","author":"SE Nissen","year":"2022","unstructured":"Nissen, S. E. When is a placebo not a placebo. JAMA Cardiol. 7, 1183\u20131184 (2022).","journal-title":"JAMA Cardiol."},{"key":"1037_CR149","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1161\/CIRCULATIONAHA.122.059678","volume":"146","author":"H Daida","year":"2022","unstructured":"Daida, H. Randomized trial for evaluating secondary prevention efficacy of combination therapy \u2013 statin and eicosapentaenoic acid. Circulation 146, e569\u2013e611 (2022).","journal-title":"Circulation"},{"key":"1037_CR150","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/cells10030501","volume":"10","author":"Y-J Lee","year":"2021","unstructured":"Lee, Y.-J. et al. STAT6 signaling mediates PPAR\u03b3 activation and resolution of acute sterile inflammation in mice. Cells 10, 501 (2021).","journal-title":"Cells"},{"key":"1037_CR151","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.29292","volume":"6","author":"X Xian","year":"2017","unstructured":"Xian, X. et al. LRP1 integrates murine macrophage cholesterol homeostasis and inflammatory responses in atherosclerosis. eLife 6, e29292 (2017).","journal-title":"eLife"},{"key":"1037_CR152","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.immuni.2009.06.018","volume":"31","author":"N A-Gonzalez","year":"2009","unstructured":"A-Gonzalez, N. et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31, 245\u2013258 (2009).","journal-title":"Immunity"},{"key":"1037_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.06.223","volume":"287","author":"S Ivanov","year":"2019","unstructured":"Ivanov, S. et al. Lysosomal cholesterol hydrolysis couples efferocytosis to anti-inflammatory oxysterol production. Atherosclerosis 287, e77 (2019).","journal-title":"Atherosclerosis"},{"key":"1037_CR154","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1161\/ATVBAHA.122.317583","volume":"42","author":"K Endo-Umeda","year":"2022","unstructured":"Endo-Umeda, K. et al. Myeloid LXR (liver X receptor) deficiency induces inflammatory gene expression in foamy macrophages and accelerates atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 42, 719\u2013731 (2022).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR155","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1161\/ATVBAHA.120.315622","volume":"41","author":"A Yurdagul Jr","year":"2021","unstructured":"Yurdagul, A. Jr et al. ODC (ornithine decarboxylase)-dependent putrescine synthesis maintains MerTK (MER yrosine-protein kinase) expression to drive resolution. Arterioscler. Thromb. Vasc. Biol. 41, e144\u2013e159 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR156","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131355","volume":"4","author":"W Cai","year":"2019","unstructured":"Cai, W. et al. STAT6\/Arg1 promotes microglia\/macrophage efferocytosis and inflammation resolution in stroke mice. JCI Insight 4, e131355 (2019).","journal-title":"JCI Insight"},{"key":"1037_CR157","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41586-018-0735-5","volume":"563","author":"S Morioka","year":"2018","unstructured":"Morioka, S. et al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature 563, 714\u2013718 (2018).","journal-title":"Nature"},{"key":"1037_CR158","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.cmet.2022.12.005","volume":"35","author":"Y-T Wang","year":"2023","unstructured":"Wang, Y.-T. et al. Metabolic adaptation supports enhanced macrophage efferocytosis in limited-oxygen environments. Cell Metab. 35, 316\u2013331.e6 (2023).","journal-title":"Cell Metab."},{"key":"1037_CR159","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1161\/01.ATV.0000166517.18801.a7","volume":"25","author":"DM Schrijvers","year":"2005","unstructured":"Schrijvers, D. M., Meyer, G. R. Y.De, Kockx, M. M., Herman, A. G. & Martinet, W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 1256\u20131261 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR160","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fcvm.2017.00086","volume":"4","author":"A Yurdagul","year":"2018","unstructured":"Yurdagul, A., Doran, A. C., Cai, B., Fredman, G. & Tabas, I. A. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front. Cardiovasc. Med. 4, 86 (2018).","journal-title":"Front. Cardiovasc. Med."},{"key":"1037_CR161","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41586-019-1167-6","volume":"569","author":"C Silvestre-Roig","year":"2019","unstructured":"Silvestre-Roig, C. et al. Externalized histone H4 orchestrates chronic inflammation by inducing lytic cell death. Nature 569, 236\u2013240 (2019).","journal-title":"Nature"},{"key":"1037_CR162","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1161\/01.CIR.97.23.2307","volume":"97","author":"MM Kockx","year":"1998","unstructured":"Kockx, M. M. et al. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 97, 2307\u20132315 (1998).","journal-title":"Circulation"},{"key":"1037_CR163","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1161\/CIRCRESAHA.110.217281","volume":"106","author":"L Yvan-Charvet","year":"2010","unstructured":"Yvan-Charvet, L. et al. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ. Res. 106, 1861\u20131869 (2010).","journal-title":"Circ. Res."},{"key":"1037_CR164","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0928-4680(00)00053-5","volume":"7","author":"K Kannan","year":"2000","unstructured":"Kannan, K. & Jain, S. K. Oxidative stress and apoptosis. Pathophysiology 7, 153\u2013163 (2000).","journal-title":"Pathophysiology"},{"key":"1037_CR165","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10495-017-1413-z","volume":"22","author":"M Sachet","year":"2017","unstructured":"Sachet, M., Liang, Y. Y. & Oehler, R. The immune response to secondary necrotic cells. Apoptosis 22, 1189\u20131204 (2017).","journal-title":"Apoptosis"},{"key":"1037_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24890-3","volume":"12","author":"MB Wright","year":"2021","unstructured":"Wright, M. B. et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat. Commun. 12, 4662 (2021).","journal-title":"Nat. Commun."},{"key":"1037_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46467-4","volume":"13","author":"N Hoeffner","year":"2023","unstructured":"Hoeffner, N., Paul, A. & Goo, Y.-H. Drug screen identifies verteporfin as a regulator of lipid metabolism in macrophage foam cells. Sci. Rep. 13, 19588 (2023).","journal-title":"Sci. Rep."},{"key":"1037_CR168","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1161\/01.ATV.0000184783.04864.9f","volume":"25","author":"I Tabas","year":"2005","unstructured":"Tabas, I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 2255\u20132264 (2005).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR169","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1073\/pnas.91.8.3265","volume":"91","author":"GR Sambrano","year":"1994","unstructured":"Sambrano, G. R., Parthasarathy, S. & Steinberg, D. Recognition of oxidatively damaged erythrocytes by a macrophage receptor with specificity for oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA 91, 3265\u20133269 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1037_CR170","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1073\/pnas.92.5.1396","volume":"92","author":"GR Sambrano","year":"1995","unstructured":"Sambrano, G. R. & Steinberg, D. Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine. Proc. Natl Acad. Sci. USA 92, 1396\u20131400 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1037_CR171","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1074\/jbc.M209634200","volume":"278","author":"YI Miller","year":"2003","unstructured":"Miller, Y. I. et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4\/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278, 1561\u20131568 (2003).","journal-title":"J. Biol. Chem."},{"key":"1037_CR172","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1365-2249.1995.tb06652.x","volume":"102","author":"R Wu","year":"1995","unstructured":"Wu, R. & Lefvert, A. K. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin. Exp. Immunol. 102, 174\u2013180 (1995).","journal-title":"Clin. Exp. Immunol."},{"key":"1037_CR173","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1073\/pnas.96.11.6353","volume":"96","author":"M-K Chang","year":"1999","unstructured":"Chang, M.-K. et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc. Natl Acad. Sci. USA 96, 6353\u20136358 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1037_CR174","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.4049\/jimmunol.1002080","volume":"185","author":"DA Fraser","year":"2010","unstructured":"Fraser, D. A. & Tenner, A. J. Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages. J. Immunol. 185, 3932\u20133939 (2010).","journal-title":"J. Immunol."},{"key":"1037_CR175","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1111\/j.1742-4658.2010.07762.x","volume":"277","author":"K Duus","year":"2010","unstructured":"Duus, K. et al. Direct interaction between CD91 and C1q. FEBS J. 277, 3526\u20133537 (2010).","journal-title":"FEBS J."},{"key":"1037_CR176","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4049\/jimmunol.1601445","volume":"198","author":"MC Pulanco","year":"2017","unstructured":"Pulanco, M. C. et al. Complement protein C1q enhances macrophage foam cell survival and efferocytosis. J. Immunol. 198, 472\u2013480 (2017).","journal-title":"J. Immunol."},{"key":"1037_CR177","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/CIRCULATIONAHA.117.030389","volume":"137","author":"Y Kojima","year":"2018","unstructured":"Kojima, Y. et al. Proefferocytic therapy promotes transforming growth factor-\u03b2 signaling and prevents aneurysm formation. Circulation 137, 750\u2013753 (2018).","journal-title":"Circulation"},{"key":"1037_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14802","volume":"8","author":"PA Betancur","year":"2017","unstructured":"Betancur, P. A. et al. A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer. Nat. Commun. 8, 14802 (2017).","journal-title":"Nat. Commun."},{"key":"1037_CR179","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s40425-019-0812-9","volume":"7","author":"X Zhang","year":"2019","unstructured":"Zhang, X. et al. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer. J. Immunother. Cancer 7, 346 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1037_CR180","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1046\/j.1365-2249.2000.01281.x","volume":"121","author":"H Bruunsgaard","year":"2000","unstructured":"Bruunsgaard, H., Skinh\u00f8j, P., Pedersen, A. N., Schroll, M. & Pedersen, B. K. Ageing, tumour necrosis factor\u2010alpha (TNF\u2010\u03b1) and atherosclerosis. Clin. Exp. Immunol. 121, 255\u2013260 (2000).","journal-title":"Clin. Exp. Immunol."},{"key":"1037_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-020-00267-z","volume":"18","author":"K Kohno","year":"2021","unstructured":"Kohno, K. et al. Inflammatory M1-like macrophages polarized by NK-4 undergo enhanced phenotypic switching to an anti-inflammatory M2-like phenotype upon co-culture with apoptotic cells. J. Inflamm. 18, 2 (2021).","journal-title":"J. Inflamm."},{"key":"1037_CR182","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/fon-2022-0975","volume":"19","author":"B Paul","year":"2023","unstructured":"Paul, B. et al. A phase II multi-arm study of magrolimab combinations in patients with relapsed\/refractory multiple myeloma. Futur. Oncol. 19, 7\u201317 (2023).","journal-title":"Futur. Oncol."},{"key":"1037_CR183","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman, D. A. et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J. Clin. Oncol. 41, 2815\u20132826 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1037_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04827576 (2024)."},{"key":"1037_CR185","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02216409 (2019)."},{"key":"1037_CR186","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1161\/CIRCRESAHA.122.321692","volume":"132","author":"D Wong","year":"2023","unstructured":"Wong, D. et al. FHL5 controls vascular disease-associated gene programs in smooth muscle cells. Circ. Res. 132, 1144\u20131161 (2023).","journal-title":"Circ. Res."},{"key":"1037_CR187","doi-asserted-by":"publisher","first-page":"113380","DOI":"10.1016\/j.celrep.2023.113380","volume":"42","author":"JV Mosquera","year":"2023","unstructured":"Mosquera, J. V. et al. Integrative single-cell meta-analysis reveals disease-relevant vascular cell states and markers in human atherosclerosis. Cell Rep. 42, 113380 (2023).","journal-title":"Cell Rep."},{"key":"1037_CR188","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1161\/CIRCULATIONAHA.120.048378","volume":"142","author":"H Pan","year":"2020","unstructured":"Pan, H. et al. Single-cell genomics reveals a novel cell state during smooth muscle cell phenotypic switching and potential therapeutic targets for atherosclerosis in mouse and human. Circulation 142, 2060\u20132075 (2020).","journal-title":"Circulation"},{"key":"1037_CR189","doi-asserted-by":"publisher","first-page":"1273596","DOI":"10.3389\/fcvm.2023.1273596","volume":"10","author":"L Luo","year":"2023","unstructured":"Luo, L., Fu, C., Bell, C. F., Wang, Y. & Leeper, N. J. Role of vascular smooth muscle cell clonality in atherosclerosis. Front. Cardiovasc. Med. 10, 1273596 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"1037_CR190","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1089\/dna.2020.5647","volume":"40","author":"MAEM Sihombing","year":"2021","unstructured":"Sihombing, M. A. E. M. et al. Unexpected role of nonimmune cells: amateur phagocytes. DNA Cell Biol. 40, 157\u2013171 (2021).","journal-title":"DNA Cell Biol."},{"key":"1037_CR191","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2006-06-026187","volume":"109","author":"T Kirsch","year":"2007","unstructured":"Kirsch, T. et al. Engulfment of apoptotic cells by microvascular endothelial cells induces proinflammatory responses. Blood 109, 2854\u20132862 (2007).","journal-title":"Blood"},{"key":"1037_CR192","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nm.3866","volume":"21","author":"LS Shankman","year":"2015","unstructured":"Shankman, L. S. et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat. Med. 21, 628\u2013637 (2015).","journal-title":"Nat. Med."},{"key":"1037_CR193","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1073\/pnas.1621375114","volume":"114","author":"G Wernig","year":"2017","unstructured":"Wernig, G. et al. Unifying mechanism for different fibrotic diseases. Proc. Natl Acad. Sci. USA 114, 4757\u20134762 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1037_CR194","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1084\/jem.20070885","volume":"204","author":"M Nahrendorf","year":"2007","unstructured":"Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204, 3037\u20133047 (2007).","journal-title":"J. Exp. Med."},{"key":"1037_CR195","first-page":"187","volume":"38","author":"M Horckmans","year":"2017","unstructured":"Horckmans, M. et al. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur. Hear. J. 38, 187\u2013197 (2017).","journal-title":"Eur. Hear. J."},{"key":"1037_CR196","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/cvr\/cvz336","volume":"116","author":"C Peet","year":"2020","unstructured":"Peet, C., Ivetic, A., Bromage, D. I. & Shah, A. M. Cardiac monocytes and macrophages after myocardial infarction. Cardiovasc. Res. 116, 1101\u20131112 (2020).","journal-title":"Cardiovasc. Res."},{"key":"1037_CR197","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41590-018-0272-2","volume":"20","author":"SA Dick","year":"2019","unstructured":"Dick, S. A. et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. Nat. Immunol. 20, 29\u201339 (2019).","journal-title":"Nat. Immunol."},{"key":"1037_CR198","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-019-1802-2","volume":"577","author":"RJ Vagnozzi","year":"2020","unstructured":"Vagnozzi, R. J. et al. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature 577, 405\u2013409 (2020).","journal-title":"Nature"},{"key":"1037_CR199","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/1479164115582351","volume":"12","author":"C Roma-Lavisse","year":"2015","unstructured":"Roma-Lavisse, C. et al. M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes. Diabetes Vasc. Dis. Res. 12, 279\u2013289 (2015).","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"1037_CR200","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1161\/CIRCRESAHA.117.311327","volume":"121","author":"M DeBerge","year":"2017","unstructured":"DeBerge, M. et al. MerTK cleavage on resident cardiac macrophages compromises repair after myocardial ischemia reperfusion injury. Circ. Res. 121, 930\u2013940 (2017).","journal-title":"Circ. Res."},{"key":"1037_CR201","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/HYPERTENSIONAHA.117.09465","volume":"70","author":"K-Q Deng","year":"2018","unstructured":"Deng, K.-Q. et al. Restoration of circulating MFGE8 (milk fat globule-EGF factor 8) attenuates cardiac hypertrophy through inhibition of Akt pathway. Hypertension 70, 770\u2013779 (2018).","journal-title":"Hypertension"},{"key":"1037_CR202","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jacbts.2017.03.013","volume":"2","author":"S Zhang","year":"2017","unstructured":"Zhang, S. et al. Acute CD47 blockade during ischemic myocardial reperfusion enhances phagocytosis-associated cardiac repair. JACC Basic. Transl. Sci. 2, 386\u2013397 (2017).","journal-title":"JACC Basic. Transl. Sci."},{"key":"1037_CR203","doi-asserted-by":"publisher","first-page":"10849","DOI":"10.1007\/s11033-022-07725-2","volume":"49","author":"A Mahmoudi","year":"2022","unstructured":"Mahmoudi, A. et al. Effect of diabetes on efferocytosis process. Mol. Biol. Rep. 49, 10849\u201310863 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"1037_CR204","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41586-022-04754-6","volume":"606","author":"S Maschalidi","year":"2022","unstructured":"Maschalidi, S. et al. Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. Nature 606, 776\u2013784 (2022).","journal-title":"Nature"},{"key":"1037_CR205","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2337\/diacare.14.5.366","volume":"14","author":"MI Harris","year":"1991","unstructured":"Harris, M. I. Hypercholesterolemia in diabetes and glucose intolerance in the U.S. population. Diabetes Care 14, 366\u2013374 (1991).","journal-title":"Diabetes Care"},{"key":"1037_CR206","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12933-022-01554-0","volume":"21","author":"X Hu","year":"2022","unstructured":"Hu, X. et al. The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus. Cardiovasc. Diabetol. 21, 117 (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"1037_CR207","doi-asserted-by":"publisher","first-page":"RV17023","DOI":"10.5551\/jat.RV17023","volume":"25","author":"T Hirano","year":"2018","unstructured":"Hirano, T. Pathophysiology of diabetic dyslipidemia. J. Atheroscler. Thromb. 25, RV17023 (2018).","journal-title":"J. Atheroscler. Thromb."},{"key":"1037_CR208","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062188","volume":"12","author":"T Okdahl","year":"2022","unstructured":"Okdahl, T. et al. Low-grade inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient clinic. BMJ Open. 12, e062188 (2022).","journal-title":"BMJ Open."},{"key":"1037_CR209","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.2174\/1381612811319320005","volume":"19","author":"T Fiorentino","year":"2013","unstructured":"Fiorentino, T., Prioletta, A., Zuo, P. & Folli, F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr. Pharm. Des. 19, 5695\u20135703 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"1037_CR210","doi-asserted-by":"publisher","first-page":"35016","DOI":"10.1038\/srep35016","volume":"6","author":"HHL Tseng","year":"2016","unstructured":"Tseng, H. H. L., Vong, C. T., Kwan, Y. W., Lee, S. M.-Y. & Hoi, M. P. M. TRPM2 regulates TXNIP-mediated NLRP3 inflammasome activation via interaction with p47 phox under high glucose in human monocytic cells. Sci. Rep. 6, 35016 (2016).","journal-title":"Sci. Rep."},{"key":"1037_CR211","doi-asserted-by":"publisher","first-page":"900254","DOI":"10.3389\/fimmu.2022.900254","volume":"13","author":"J Ye","year":"2022","unstructured":"Ye, J. et al. Diabetes mellitus promotes the development of atherosclerosis: the role of NLRP3. Front. Immunol. 13, 900254 (2022).","journal-title":"Front. Immunol."},{"key":"1037_CR212","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ecl.2021.05.005","volume":"50","author":"W Crasto","year":"2021","unstructured":"Crasto, W., Patel, V., Davies, M. J. & Khunti, K. Prevention of microvascular complications of diabetes. Endocrinol. Metab. Clin. North. Am. 50, 431\u2013455 (2021).","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"1037_CR213","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.biopha.2007.07.007","volume":"62","author":"H Salman","year":"2008","unstructured":"Salman, H., Bergman, M., Djaldetti, M. & Bessler, H. Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomed. Pharmacother. 62, 41\u201345 (2008).","journal-title":"Biomed. Pharmacother."},{"key":"1037_CR214","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.4049\/jimmunol.176.12.7657","volume":"176","author":"K Morimoto","year":"2006","unstructured":"Morimoto, K. et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J. Immunol. 176, 7657\u20137665 (2006).","journal-title":"J. Immunol."},{"key":"1037_CR215","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrc725","volume":"2","author":"E Sahai","year":"2002","unstructured":"Sahai, E. & Marshall, C. J. RHO-GTPases and cancer. Nat. Rev. Cancer 2, 133\u2013142 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"1037_CR216","doi-asserted-by":"publisher","first-page":"108282","DOI":"10.1016\/j.pharmthera.2022.108282","volume":"238","author":"A Tajbakhsh","year":"2022","unstructured":"Tajbakhsh, A. et al. Statin-regulated phagocytosis and efferocytosis in physiological and pathological conditions. Pharmacol. Ther. 238, 108282 (2022).","journal-title":"Pharmacol. Ther."},{"key":"1037_CR217","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s44161-022-00023-x","volume":"1","author":"K-U Jarr","year":"2022","unstructured":"Jarr, K.-U. et al. The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis. Nat. Cardiovasc. Res. 1, 253\u2013262 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1037_CR218","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2006","unstructured":"Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495\u20131504 (2004); correction 354, 778 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1037_CR219","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/hc0602.103586","volume":"105","author":"AW Chan","year":"2002","unstructured":"Chan, A. W. et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105, 691\u2013696 (2002).","journal-title":"Circulation"},{"key":"1037_CR220","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/01.hpc.0000154979.98731.5d","volume":"4","author":"KK Ray","year":"2005","unstructured":"Ray, K. K. & Cannon, C. P. Time to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease. Crit. Pathw. Cardiol. 4, 43\u201345 (2005).","journal-title":"Crit. Pathw. Cardiol."},{"key":"1037_CR221","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cpt.2349","volume":"110","author":"G McInnes","year":"2021","unstructured":"McInnes, G., Yee, S. W., Pershad, Y. & Altman, R. B. Genomewide association studies in pharmacogenomics. Clin. Pharmacol. Ther. 110, 637\u2013648 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1037_CR222","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/FPC.0b013e32833d7b45","volume":"23","author":"AA Motsinger-Reif","year":"2013","unstructured":"Motsinger-Reif, A. A. et al. Genome-wide association studies in pharmacogenomics. Pharmacogenet. Genom. 23, 383\u2013394 (2013).","journal-title":"Pharmacogenet. Genom."},{"key":"1037_CR223","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1161\/CIRCRESAHA.115.307906","volume":"118","author":"V Nanda","year":"2016","unstructured":"Nanda, V. et al. CDKN2B regulates TGF\u03b2 signaling and smooth muscle cell investment of hypoxic neovessels. Circ. Res. 118, 230\u2013240 (2016).","journal-title":"Circ. Res."},{"key":"1037_CR224","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145275","volume":"131","author":"C Kasikara","year":"2021","unstructured":"Kasikara, C. et al. Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis. J. Clin. Invest. 131, e145275 (2021).","journal-title":"J. Clin. Invest."},{"key":"1037_CR225","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12920-022-01216-w","volume":"15","author":"AJ Alsheikh","year":"2022","unstructured":"Alsheikh, A. J. et al. The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases. BMC Med. Genom. 15, 74 (2022).","journal-title":"BMC Med. Genom."},{"key":"1037_CR226","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01419-z","volume":"15","author":"T Feehley","year":"2023","unstructured":"Feehley, T., O\u2019Donnell, C. W., Mendlein, J., Karande, M. & McCauley, T. Drugging the epigenome in the age of precision medicine. Clin. Epigenetics 15, 6 (2023).","journal-title":"Clin. Epigenetics"},{"key":"1037_CR227","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-024-07087-8","volume":"627","author":"MA Cappelluti","year":"2024","unstructured":"Cappelluti, M. A. et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature 627, 416\u2013423 (2024).","journal-title":"Nature"},{"key":"1037_CR228","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nbt.3853","volume":"35","author":"TS Klann","year":"2017","unstructured":"Klann, T. S. et al. CRISPR\u2013Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat. Biotechnol. 35, 561\u2013568 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1037_CR229","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0014-5793(95)00930-8","volume":"371","author":"LP Wennogle","year":"1995","unstructured":"Wennogle, L. P. et al. Comparison of recombinant cyclooxygenase\u20102 to native isoforms: aspirin labeling of the active site. FEBS Lett. 371, 315\u2013320 (1995).","journal-title":"FEBS Lett."},{"key":"1037_CR230","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.2023.12905","volume":"330","author":"SGK Yoo","year":"2023","unstructured":"Yoo, S. G. K. et al. Aspirin for secondary prevention of cardiovascular disease in 51 low-, middle-, and high-income countries. JAMA 330, 715\u2013724 (2023).","journal-title":"JAMA"},{"key":"1037_CR231","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2267-z","volume":"581","author":"EV Minikel","year":"2020","unstructured":"Minikel, E. V. et al. Evaluating drug targets through human loss-of-function genetic variation. Nature 581, 459\u2013464 (2020).","journal-title":"Nature"},{"key":"1037_CR232","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1016\/j.cell.2022.11.029","volume":"185","author":"S Morioka","year":"2022","unstructured":"Morioka, S. et al. Chimeric efferocytic receptors improve apoptotic cell clearance and alleviate inflammation. Cell 185, 4887\u20134903.e17 (2022).","journal-title":"Cell"},{"key":"1037_CR233","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1136\/heart.89.10.1262","volume":"89","author":"A Lafont","year":"2003","unstructured":"Lafont, A. Basic aspects of plaque vulnerability. Heart 89, 1262 (2003).","journal-title":"Heart"},{"key":"1037_CR234","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1172\/JCI16790","volume":"111","author":"DH McDermott","year":"2003","unstructured":"McDermott, D. H. et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest. 111, 1241\u20131250 (2003).","journal-title":"J. Clin. Invest."},{"key":"1037_CR235","doi-asserted-by":"publisher","first-page":"C1267","DOI":"10.1152\/ajpcell.00152.2010","volume":"299","author":"A Friggeri","year":"2010","unstructured":"Friggeri, A. et al. HMGB1 inhibits macrophage activity in efferocytosis through binding to the \u03b1v\u03b23-integrin. Am. J. Physiol. Cell Physiol. 299, C1267\u2013C1276 (2010).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1037_CR236","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2021.02.025","volume":"518","author":"W Chen","year":"2021","unstructured":"Chen, W. et al. The ABCA1-efferocytosis axis: a new strategy to protect against atherosclerosis. Clin. Chim. Acta 518, 1\u20138 (2021).","journal-title":"Clin. Chim. Acta"},{"key":"1037_CR237","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1161\/01.ATV.0000035408.93749.71","volume":"22","author":"J Rong","year":"2008","unstructured":"Rong, J. et al. Lysophasphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Asterioscler. Thromb. Vasc. Biol. 22, 1617\u20131623 (2008).","journal-title":"Asterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR238","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1096\/fj.08-107169","volume":"22","author":"DR Gude","year":"2008","unstructured":"Gude, D. R. et al. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine\u20101\u2010phosphate as a \u201ccome\u2010and\u2010get\u2010me\u201d signal. FASEB J. 22, 2629\u20132638 (2008).","journal-title":"FASEB J."},{"key":"1037_CR239","doi-asserted-by":"publisher","first-page":"ra79","DOI":"10.1126\/scisignal.aaa2581","volume":"8","author":"S Galvani","year":"2015","unstructured":"Galvani, S. et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci. Signal. 8, ra79 (2015).","journal-title":"Sci. Signal."},{"key":"1037_CR240","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2353\/ajpath.2007.060406","volume":"170","author":"VK Bhatia","year":"2007","unstructured":"Bhatia, V. K. et al. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am. J. Pathol. 170, 416\u2013426 (2007).","journal-title":"Am. J. Pathol."},{"key":"1037_CR241","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41590-018-0249-1","volume":"20","author":"I Kourtzelis","year":"2019","unstructured":"Kourtzelis, I. et al. DEL-1 promotes macrophage efferocytosis and clearance of inflammation. Nat. Immunol. 20, 40\u201349 (2019).","journal-title":"Nat. Immunol."},{"key":"1037_CR242","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1253\/circj.CJ-16-0808","volume":"80","author":"A Kakino","year":"2016","unstructured":"Kakino, A., Fujita, Y., Nakano, A., Horiuchi, S. & Sawamura, T. Developmental endothelial locus-1 (Del-1) inhibits oxidized low-density lipoprotein activity by direct binding, and its overexpression attenuates atherogenesis in mice. Circ. J. 80, 2541\u20132549 (2016).","journal-title":"Circ. J."},{"key":"1037_CR243","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-09-528752","volume":"123","author":"JH van der Meer","year":"2014","unstructured":"van der Meer, J. H., van der Poll, T. & van \u2018t Veer, C. TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis. Blood 123, 2460\u20132469 (2014).","journal-title":"Blood"},{"key":"1037_CR244","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/path.2381","volume":"216","author":"E Lutgens","year":"2008","unstructured":"Lutgens, E. et al. Genetic loss of Gas6 induces plaque stability in experimental atherosclerosis. J. Pathol. 216, 55\u201363 (2008).","journal-title":"J. Pathol."},{"key":"1037_CR245","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2012-05-433730","volume":"121","author":"RS Robins","year":"2013","unstructured":"Robins, R. S. et al. Vascular Gas6 contributes to thrombogenesis and promotes tissue factor up-regulation after vessel injury in mice. Blood 121, 692\u2013699 (2013).","journal-title":"Blood"},{"key":"1037_CR246","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117787","volume":"10","author":"Y Tang","year":"2015","unstructured":"Tang, Y. et al. Mertk deficiency affects macrophage directional migration via disruption of cytoskeletal organization. PLoS ONE 10, e0117787 (2015).","journal-title":"PLoS ONE"},{"key":"1037_CR247","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cub.2009.01.042","volume":"19","author":"D Park","year":"2009","unstructured":"Park, D., Hochreiter-Hufford, A. & Ravichandran, K. S. The phosphatidylserine receptor TIM-4 does not mediate direct signaling. Curr. Biol. 19, 346\u2013351 (2009).","journal-title":"Curr. Biol."},{"key":"1037_CR248","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/cells9071625","volume":"9","author":"B Moon","year":"2020","unstructured":"Moon, B. et al. Mertk interacts with Tim-4 to enhance Tim-4-mediated efferocytosis. Cells 9, 1625 (2020).","journal-title":"Cells"},{"key":"1037_CR249","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1161\/ATVBAHA.115.306860","volume":"36","author":"AC Foks","year":"2018","unstructured":"Foks, A. C. et al. Blockade of Tim-1 and Tim-4 enhances atherosclerosis in low-density lipoprotein receptor\u2013deficient mice. Arterioscler. Thromb. Vasc. Biol. 36, 456\u2013465 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR250","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nature06329","volume":"450","author":"D Park","year":"2007","unstructured":"Park, D. et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO\/Dock180\/Rac module. Nature 450, 430\u2013434 (2007).","journal-title":"Nature"},{"key":"1037_CR251","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1172\/JCI80300","volume":"125","author":"AM Fond","year":"2015","unstructured":"Fond, A. M., Lee, C. S., Schulman, I. G., Kiss, R. S. & Ravichandran, K. S. Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1. J. Clin. Invest. 125, 2748\u20132758 (2015).","journal-title":"J. Clin. Invest."},{"key":"1037_CR252","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/sj.cdd.4402242","volume":"15","author":"S-Y Park","year":"2008","unstructured":"Park, S.-Y. et al. Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ. 15, 192\u2013201 (2008).","journal-title":"Cell Death Differ."},{"key":"1037_CR253","doi-asserted-by":"publisher","first-page":"818662","DOI":"10.3389\/fcvm.2022.818662","volume":"9","author":"Y Kayashima","year":"2022","unstructured":"Kayashima, Y. et al. Reduction of stabilin-2 contributes to a protection against atherosclerosis. Front. Cardiovasc. Med. 9, 818662 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"1037_CR254","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1136\/heartjnl-2019-315103","volume":"105","author":"WS Jenkins","year":"2019","unstructured":"Jenkins, W. S. et al. In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis. Heart 105, 1868\u20131875 (2019).","journal-title":"Heart"},{"key":"1037_CR255","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1194\/jlr.M056689","volume":"56","author":"H Tao","year":"2015","unstructured":"Tao, H. et al. Macrophage SR-BI mediates efferocytosis via Src\/PI3K\/Rac1 signaling and reduces atherosclerotic lesion necrosis. J. Lipid Res. 56, 1449\u20131460 (2015).","journal-title":"J. Lipid Res."},{"key":"1037_CR256","doi-asserted-by":"publisher","first-page":"7330","DOI":"10.4049\/jimmunol.174.11.7330","volume":"174","author":"L Falasca","year":"2005","unstructured":"Falasca, L. et al. Transglutaminase type II is a key element in the regulation of the anti-inflammatory response elicited by apoptotic cell engulfment. J. Immunol. 174, 7330\u20137340 (2005).","journal-title":"J. Immunol."},{"key":"1037_CR257","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/eji.201141719","volume":"41","author":"E Thorp","year":"2011","unstructured":"Thorp, E., Subramanian, M. & Tabas, I. The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur. J. Immunol. 41, 2515\u20132518 (2011).","journal-title":"Eur. J. Immunol."},{"key":"1037_CR258","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1161\/01.ATV.0000203503.82693.c1","volume":"26","author":"WA Boisvert","year":"2006","unstructured":"Boisvert, W. A. et al. Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size. Arterioscler. Thromb. Vasc. Biol. 26, 563\u2013569 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1037_CR259","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1161\/01.CIR.91.11.2703","volume":"91","author":"JM Isner","year":"1995","unstructured":"Isner, J. M., Kearney, M., Bortman, S. & Passeri, J. Apoptosis in human atherosclerosis and restenosis. Circulation 91, 2703\u20132711 (1995).","journal-title":"Circulation"},{"key":"1037_CR260","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson, N. C., Rieder, F. & Wynn, T. A. Fibrosis: from mechanisms to medicines. Nature 587, 555\u2013566 (2020).","journal-title":"Nature"},{"key":"1037_CR261","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.rmed.2012.08.020","volume":"106","author":"K Morimoto","year":"2012","unstructured":"Morimoto, K., Janssen, W. J. & Terada, M. Defective efferocytosis by alveolar macrophages in IPF patients. Respir. Med. 106, 1800\u20131803 (2012).","journal-title":"Respir. Med."},{"key":"1037_CR262","doi-asserted-by":"publisher","first-page":"eabp8309","DOI":"10.1126\/scitranslmed.abp8309","volume":"14","author":"H Shi","year":"2022","unstructured":"Shi, H. et al. CD47-SIRP\u03b1 axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis. Sci. Transl. Med. 14, eabp8309 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1037_CR263","first-page":"5908","volume":"12","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. CD47 antibody suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy. Am. J. Transl. Res. 12, 5908\u20135923 (2019).","journal-title":"Am. J. Transl. Res."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-024-01037-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-024-01037-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-024-01037-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:47:15Z","timestamp":1728989235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-024-01037-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":263,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1038\/s41569-024-01037-7","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"23 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.J.L. is co-founder and director of Bitterroot Bio, a biotechnology company focused on immunomodulatory therapies for cardiovascular disease. S.S.A. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}